

William DuVal

Special Counsel



wduval@cooley.com

+1 703 456 8663

Reston

Emerging Companies
Mergers and Acquisitions
Venture Capital
Capital Markets

William primarily represents high-growth companies in the life sciences, digital health and tech sectors, along with leading venture capital firms in their investment activities in the same sectors. His practice focuses on public and private offerings, venture capital transactions, strategic partnerships and collaborations, M&A, and corporate governance.

William received his JD and MBA from the University of Virginia, where he was president of the JD/MBA Society. He received his BS from the University of Virginia McIntire School of Commerce, with concentrations in finance and marketing.

Representative company-side and underwriter-side public offerings:

- Aclaris Therapeutics – \$92.9 million follow-on offering
- Epizyme – \$75 million follow-on offering
- argenx – \$862.5 million follow-on offering
- Autolus Therapeutics – \$150 million initial public offering (IPO)
- Helius Medical Technologies – \$16 million follow-on offering
- Biohaven Pharmaceutical Holding – \$193.6 million IPO

Education

University of Virginia School of Law
JD, 2016

University of Virginia Darden School of Business
MBA, 2016

University of Virginia McIntire School of Commerce
BS, 2008

Admissions & Credentials

Virginia